Molecular Partners And Orano Med Expand Collaboration To Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Molecular Partners and Orano Med have expanded their collaboration to co-develop four Radio-DARPin programs. Each company will now have the right to commercialize two programs, with Molecular Partners holding rights to the second nominated Radio-DARPin Candidate and the first program MP0712 targeting DLL3.
October 22, 2024 | 6:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Molecular Partners has expanded its collaboration with Orano Med, allowing it to commercialize two Radio-DARPin programs, including MP0712 targeting DLL3. This expansion could enhance Molecular Partners' product pipeline and market potential.
The expanded collaboration allows Molecular Partners to commercialize two programs instead of one, potentially increasing its market presence and revenue opportunities. The focus on Radio-DARPin therapeutics, including MP0712, could enhance its product offerings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90